



To

Securities and Exchange Commission of Brazil (CVM)

Business Monitoring Management – 1

At.: Mrs. Maria Luisa Azevedo Wernesbach Federal Capital Market Inspector Mrs. Nilza Maria Silva de Oliveira Manager

Ref.: Official Letter nº 298/2025/CVM/SEP/GEA-1 Request for clarification regarding news – CVM Process nº 19957.016352/2025-72

Dear Sirs,

In compliance with Official Letter No. 298/2025/CVM/SEP/GEA-1, attached to this response ("Official Letter"), Braskem S.A. ("Braskem" or Company") presents the following clarifications regarding the news published on 11/06/2025 in the Broadcast column of the newspaper O Estado de São Paulo, which contains the following statements:

"Braskem signals to creditors abroad that it will have a restructuring plan by January

Braskem's management was recently in talks with creditors who have securities issued by the company abroad (bonds) and signaled that it will present a plan to restructure its financial liabilities by January, Coluna learned. On that date, more than US\$170 million in interest accrues on the company's securities circulating abroad, according to the contracts for these securities that are available on the company's website. According to three sources heard by the Column, the comment was made in response to a question from these creditors about the payment of such a commitment and specifically about the 2028 bond, whose interest is the first to mature in January, on the 10th, totaling US\$28 million."

As disclosed through the Material Fact dated 09/26/2025, Braskem hired financial and legal advisors to assist it in preparing a diagnosis of economic-financial alternatives aimed at optimizing its capital structure.

The work related to the aforementioned diagnosis is currently underway and, as part of such work, the Company's advisors have been contacted by creditors and have held preliminary conversations with the aim of obtaining the necessary information to evaluate and propose to management alternatives for optimizing the Company's capital structure.



Nevertheless, we reiterate that the diagnosis disclosed in the Material Fact dated 09/26/2025 is still ongoing and, on this date, there is no proposal, decision or deadline defined by the Company's competent bodies regarding the appropriate alternative to optimize Braskem's capital structure.

Being what we had to clarify, we made ourselves available to you for any additional clarifications regarding the topic, if necessary.

São Paulo, November 7, 2025.

Felipe Montoro Jens Chief Financial and Investor Relations Officer Braskem S.A.